Journal of Clinical Oncology, Vol 18, Issue 5
(March), 2000: 947
© 2000 American Society for Clinical Oncology
Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies
By Ivana N. M. Micallef,
Debra M. Lillington,
John Apostolidis,
John A. L. Amess,
Michael Neat,
Janet Matthews,
Taane Clark,
James M. Foran,
Ashiq Salam,
T. Andrew Lister,
Ama Z. S. Rohatiner
From the Imperial Cancer Research Fund Medical Oncology Unit, Departments of Medical Oncology and Haematology, St Bartholomew’s Hospital, London; and Imperial Cancer Research Fund Centre for Statistics in Medicine, Institute of Health Sciences, Oxford, United Kingdom.
Address reprint requests to Ama Z.S. Rohatiner, MD, Imperial Cancer Research Fund Medical Oncology Unit, Department of Medical Oncology, St Bartholomew’s Hospital, 45 Little Britain, West Smithfield, London EC1A 7BE, United Kingdom; email a.rohatiner@ icrf.icnet.uk.
PURPOSE: To evaluate the incidence of and risk factors for therapy-related myelodysplasia (tMDS) and secondary acute myelogenous leukemia (sAML), after high-dose therapy (HDT) with autologous bone marrow or peripheral-blood progenitor-cell support, in patients with non-Hodgkin’s lymphoma (NHL).
PATIENTS AND METHODS: Between January 1985 and November 1996, 230 patients underwent HDT comprising cyclophosphamide therapy and total-body irradiation, with autologous hematopoietic progenitor-cell support, as consolidation of remission. With a median follow-up of 6 years, 27 (12%) developed tMDS or sAML.
RESULTS: Median time to development of tMDS or sAML was 4.4 years (range, 11 months to 8.8 years) after HDT. Karyotyping (performed in 24 cases) at diagnosis of tMDS or sAML revealed complex karyotypes in 18 patients. Seventeen patients had monosomy 5/5q-, 15 had -7/7q-, seven had -18/18q-, seven had -13/13q-, and four had -20/20q-. Twenty-one patients died from complications of tMDS or sAML or treatment for tMDS or sAML, at a median of 10 months (range, 0 to 26 months). Sixteen died without evidence of recurrent lymphoma. Six patients were alive at a median follow-up of 6 months (range, 2 to 22 months) after diagnosis of tMDS or sAML. On multivariate analysis, prior fludarabine therapy (P = .009) and older age (P = .02) were associated with the development of tMDS or sAML. Increased interval from diagnosis to HDT and bone marrow involvement at diagnosis were of borderline significance (P = .05 and .07, respectively).
CONCLUSION: tMDS and sAML are serious complications of HDT for NHL and are associated with very poor prognosis. Alternative strategies for reducing their incidence and for treatment are needed.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Montoto, C. Moreno, E. Domingo-Domenech, C. Estany, A. Oriol, A. Altes, J. Besalduch, C. Pedro, S. Gardella, L. Escoda, et al.
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma
Haematologica,
February 1, 2008;
93(2):
207 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman
Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up
J. Clin. Oncol.,
June 20, 2007;
25(18):
2554 - 2559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol.,
April 10, 2007;
25(11):
1396 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
J. Clin. Oncol.,
August 1, 2006;
24(22):
3604 - 3610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Glass, M. Kloess, M. Bentz, G. Schlimok, W. E. Berdel, A. Feller, L. Trumper, M. Loeffler, M. Pfreundschuh, N. Schmitz, et al.
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma
Blood,
April 15, 2006;
107(8):
3058 - 3064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al.
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Blood,
December 1, 2005;
106(12):
3725 - 3732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hiddemann, C. Buske, M. Dreyling, O. Weigert, G. Lenz, R. Forstpointner, C. Nickenig, and M. Unterhalt
Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives
J. Clin. Oncol.,
September 10, 2005;
23(26):
6394 - 6399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell and J. Armitage
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2005;
80(8):
1087 - 1097.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, E. Hoster, B. Wormann, U. Duhrsen, B. Metzner, H. Eimermacher, A. Neubauer, H. Wandt, H. Steinhauer, et al.
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
J. Clin. Oncol.,
March 20, 2005;
23(9):
1984 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, E. Schiegnitz, T. Haferlach, J. Hasford, M. Unterhalt, and W. Hiddemann
Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group
J. Clin. Oncol.,
December 15, 2004;
22(24):
4926 - 4933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Forstpointner, M. Dreyling, R. Repp, S. Hermann, A. Hanel, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, R. Rohrberg, et al.
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Blood,
November 15, 2004;
104(10):
3064 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Montoto, A. Lopez-Guillermo, A. Altes, G. Perea, A. Ferrer, M. Camos, L. Villela, F. Bosch, J. Esteve, F. Cervantes, et al.
Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression
Ann. Onc.,
October 1, 2004;
15(10):
1484 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Lister
High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When?
J. Clin. Oncol.,
November 1, 2003;
21(21):
3894 - 3896.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Josting, S. Wiedenmann, J. Franklin, M. May, M. Sieber, J. Wolf, A. Engert, and V. Diehl
Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin's Disease: A Report From the German Hodgkin's Lymphoma Study Group
J. Clin. Oncol.,
September 15, 2003;
21(18):
3440 - 3446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Papadaki, K. Stamatopoulos, A. Anagnostopoulos, and A. Fassas
Rituximab-associated immune myelopathy
Blood,
August 15, 2003;
102(4):
1557 - 1558.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl, J. Franklin, M. Pfreundschuh, B. Lathan, U. Paulus, D. Hasenclever, H. Tesch, R. Herrmann, B. Dorken, H.-K. Muller-Hermelink, et al.
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
N. Engl. J. Med.,
June 12, 2003;
348(24):
2386 - 2395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Rose, A. M. Forsythe, and D. G. Maloney
Agranulocytosis unresponsive to growth factors following rituximab in vivo purging
Blood,
May 15, 2003;
101(10):
4225 - 4225.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Relling, J. M. Boyett, J. G. Blanco, S. Raimondi, F. G. Behm, J. T. Sandlund, G. K. Rivera, L. E. Kun, W. E. Evans, and C.-H. Pui
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
Blood,
May 15, 2003;
101(10):
3862 - 3867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hosing, R. M. Saliba, P. McLaughlin, B. Andersson, M. A. Rodriguez, L. Fayad, F. Cabanillas, R. E. Champlin, and I. F. Khouri
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma
Ann. Onc.,
May 1, 2003;
14(5):
737 - 744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig, C. A. White, L. I. Gordon, G. A. Wiseman, C. Emmanouilides, J. L. Murray, J. Lister, and P. S. Multani
Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 1, 2003;
21(7):
1263 - 1270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Baker, T. E. DeFor, L. J. Burns, N. K.C. Ramsay, J. P. Neglia, and L. L. Robison
New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk Factors
J. Clin. Oncol.,
April 1, 2003;
21(7):
1352 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients
J. Clin. Oncol.,
March 1, 2003;
21(5):
897 - 906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al.
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Blood,
March 1, 2003;
101(5):
2015 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ladetto, P. Corradini, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, M. Brugiatelli, P. Coser, A. Perrotti, I. Majolino, et al.
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Blood,
August 13, 2002;
100(5):
1559 - 1565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood,
July 30, 2002;
100(4):
1141 - 1152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Montoto, A. Lopez-Guillermo, A. Ferrer, M. Camos, A. Alvarez-Larran, F. Bosch, J. Blade, F. Cervantes, J. Esteve, F. Cobo, et al.
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors
Ann. Onc.,
April 1, 2002;
13(4):
523 - 530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al.
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
Ann. Onc.,
March 1, 2002;
13(3):
450 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Latagliata, M. C. Petti, S. Fenu, M. Mancini, M. A. A. Spiriti, M. Breccia, G. A. Brunetti, G. Avvisati, F. L. Coco, and F. Mandelli
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
Blood,
February 1, 2002;
99(3):
822 - 824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rambaldi, M. Lazzari, C. Manzoni, E. Carlotti, L. Arcaini, M. Baccarani, T. Barbui, C. Bernasconi, G. Dastoli, G. Fuga, et al.
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
Blood,
February 1, 2002;
99(3):
856 - 862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Lillington, I. N.M. Micallef, E. Carpenter, M. J. Neat, J. A.L. Amess, J. Matthews, N. J. Foot, B. D. Young, T. A. Lister, and A. Z.S. Rohatiner
Detection of Chromosome Abnormalities Pre-High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
May 1, 2001;
19(9):
2472 - 2481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mounier, C. Gisselbrecht, J. W. Friedberg, D. Neuberg, and A. S. Freedman
Myelodysplasia After Autotransplantation
J. Clin. Oncol.,
October 19, 2000;
18(19):
3446 - 3447.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
Blood,
June 1, 2000;
95(11):
3273 - 3279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage
Myelodysplasia and Acute Leukemia After Autologous Bone Marrow Transplantation
J. Clin. Oncol.,
March 1, 2000;
18(5):
945 - 945.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Cabanillas, S. Horning, M. Kaminski, and R. Champlin
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options
Hematology,
January 1, 2000;
2000(1):
166 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
